Pharmaceutical company Mankind Pharma has completed the deal to acquire Bharat Serum and Vaccines Limited (BSV) for Rs 13,768 crore. The company gave this information on Wednesday. According to PTI news, the company said that this strategic move is a significant leap for the company, which has established it as a market leader in the Indian women’s health and reproductive medicine market. Also provided access to other high entry barrier products in the critical care segment with established complex R&D technology platform.
Mankind Pharma’s position will be strengthened
According to the news, BSV has developed recombinant and niche biological products in-house, demonstrating its strong R&D capabilities and boasts of a strong branded product portfolio in women’s health, reproductive, critical care and immunoglobulins. Rajeev Juneja, Vice Chairman and Managing Director, Mankind Pharma, said, “Today, we warmly welcome BSV’s more than 2,500 members to the Mankind family, adding a new chapter to our exciting journey and setting the stage for accelerated growth. .
Widespread access to complex treatments will be ensured
Sanjeev Nawangul, MD & CEO, BSV, said that becoming a part of the Mankind Pharma family makes BSV bigger, stronger and better. Now together we will be able to ensure widespread access to our unique and indigenously developed complex treatments to millions of patients in India and across the world. Together we will open up new possibilities, explore opportunities and maximize potential that will help achieve our priorities and business goals. In July this year, Mankind had announced that it would acquire 100 per cent stake in BSV.
Be the first to read breaking news in Hindi aajsamacharindia.com| Today’s latest news, live news updates, read most reliable Hindi news website aajsamacharindia.com|
Like us on Facebook or follow us on Twitter for breaking news and live news updates.
